Allergy Therapeutics PLC Result of Annual General Meeting
17 12월 2024 - 12:33AM
RNS Regulatory News
RNS Number : 2798Q
Allergy Therapeutics PLC
16 December 2024
Allergy Therapeutics
plc
("Allergy
Therapeutics" or the "Group")
Result of Annual General
Meeting
16
December 2024 Allergy Therapeutics
plc (AIM:AGY), the fully integrated specialty pharmaceutical group
specialising in allergy vaccines, announces that all resolutions
proposed at the 2024 Annual General Meeting ("AGM") held today were
duly passed by shareholders on a show of hands.
Resolutions 1 to 13 (inclusive) were
proposed as ordinary resolutions and resolutions 14 to 16
(inclusive) were proposed as special resolutions. The results of
the proxy votes received ahead of the meeting are outlined in the
table below.
|
Resolution
|
For:
|
%age
|
Against:
|
%age
|
Total Votes
Cast
|
% of ISC
|
Withheld
|
|
1. Approval
of 2024 Accounts
|
4,452,448,269
|
99.99
|
3,624
|
0.01
|
4,452,453,003
|
93.41
|
1,110
|
|
2. Approval
of Directors'
Remuneration Report
|
4,451,072,636
|
99.97
|
1,379,257
|
0.03
|
4,452,453,003
|
93.41
|
1,110
|
|
3. Approval
of Directors'
Remuneration Policy
|
4,438,375,536
|
99.68
|
14,075,557
|
0.32
|
4,452,453,003
|
93.41
|
1,910
|
|
4. To elect
Dr. Shaun Furlong as a Director
|
4,450,412,573
|
99.99
|
33,283
|
0.01
|
4,452,453,003
|
93.41
|
2,007,147
|
|
5. To elect
David Ball as a Director
|
4,450,411,773
|
99.99
|
33,283
|
0.01
|
4,452,453,003
|
93.41
|
2,007,947
|
|
6. To
re-elect Anthony Parker as a Director
|
4,436,433,902
|
99.69
|
14,011,154
|
0.31
|
4,452,453,003
|
93.41
|
2,007,947
|
|
7. To
re-elect Zheqing (Simon) Shen as a Director
|
4,436,433,902
|
99.69
|
14,011,154
|
0.31
|
4,452,453,003
|
93.41
|
2,007,947
|
|
8. To
re-elect Peter Jensen O.B.E. as a Director
|
4,436,433,902
|
99.69
|
14,011,154
|
0.31
|
4,452,453,003
|
93.41
|
2,007,947
|
|
9. To
re-appoint BDO LLP as auditors of the Company
|
4,451,995,528
|
99.99
|
3,624
|
0.01
|
4,452,453,003
|
93.41
|
453,851
|
|
10. To
authorise the Directors to agree the Auditors
remuneration
|
4,452,434,231
|
99.99
|
11,625
|
0.01
|
4,452,453,003
|
93.41
|
7,147
|
|
11. To
approve the form of contract and authorise the off-market purchase
of deferred shares
|
4,452,433,431
|
99.99
|
11,625
|
0.01
|
4,452,453,003
|
93.41
|
7,947
|
|
12. To
authorise the Directors to finalise and implement arrangements for
the grant of the special, out of cycle, long term incentive awards
to the Company's senior executive team and additional option awards
to the Company's employees.
|
4,436,556,360
|
99.69
|
13,895,533
|
0.31
|
4,452,453,003
|
93.41
|
2,001,110
|
|
13. To
authorise the Directors to allot the unissued share capital up to a
specific amount (s.551)
|
4,452,337,990
|
99.99
|
15,655
|
0.01
|
4,452,453,003
|
93.41
|
99,358
|
|
14. Special
Resolution: To authorise the Directors to allot equity securities
for cash without first being required to offer such shares to
existing shareholders for a period expiring at the conclusion of
the next annual general meeting of the Company or 16 March 2026,
whichever occurs first.
|
4,438,461,319
|
99.69
|
13,892,326
|
0.31
|
4,452,453,003
|
93.41
|
99,358
|
|
15. Special
Resolution: To authorise the Directors to allot equity securities
and/or sell treasury shares for cash without first being required
to offer such securities to existing shareholders.
|
4,438,461,319
|
99.69
|
13,892,326
|
0.31
|
4,452,453,003
|
93.41
|
99,358
|
|
16. Special
Resolution: To amend the Articles of Association.
|
4,450,427,300
|
99.99
|
17,756
|
0.01
|
4,452,453,003
|
93.41
|
2,007,947
|
- ENDS -
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
Geoff Nash /Giles Balleny/ Seamus
Fricker / Rory Sale
Nigel Birks - Life Science Specialist
Sales
Tamar Cranford Smith -
Sales
+44 (0)20 7220 0500
ICR
Healthcare
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy
Therapeutics
Allergy
Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see
www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGFFUFIMELSEEE
Allergy Therapeutics (LSE:AGY)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Allergy Therapeutics (LSE:AGY)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
